There are 2789 resources available
1470P - Oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence
Presenter: Thatcher Heumann
Session: ePoster Display
1471P - Overall survival by BRCA and ATM mutation status in patients with metastatic pancreatic cancer: Findings from the PRIOR-2 study
Presenter: Gboyega Adeboyeje
Session: ePoster Display
1472P - Circulating tumor DNA in unresectable pancreatic cancer is a strong predictor of response to first-line therapy: The KRASCIPANC study
Presenter: Camille Evrard
Session: ePoster Display
1473P - Gender differences in treatment allocation and survival in a real-world metastatic pancreatic cancer cohort
Presenter: Esther Pijnappel
Session: ePoster Display
1474P - Patient characteristics and treatment patterns in patients with metastatic pancreatic cancer by BRCA/ATM status in the PRIOR-2 study
Presenter: Maria Sierra
Session: ePoster Display
1475P - Results of a randomized, double-blind, placebo-controlled, phase II study of gemcitabine and nab-paclitaxel ± olaratumab in treatment-naïve patients with unresectable metastatic pancreatic cancer
Presenter: Faithlore Gardner
Session: ePoster Display
1478P - Trends in treatment patterns among Medicare fee-for-service (FFS) patients receiving treatment for metastatic pancreatic cancer
Presenter: Gabriela Dieguez
Session: ePoster Display
1479P - Exploring second-line therapy outcome in pancreatic ductal adenocarcinoma (PDAC) patients with germlineBRCA1-2 pathogenic variants (gBRCA1-2pv)
Presenter: Giulia Orsi
Session: ePoster Display